What's Happening?
DeepIntent, a digital ad buying platform specializing in pharmaceutical marketing, has launched 'Cora,' an AI-powered platform designed to streamline and enhance healthcare advertising campaigns. This development follows DeepIntent's sale of a majority
stake to private equity firm Vitruvian Partners last year, which provided $637 million in capital to integrate generative AI tools. Cora utilizes multiple AI agents to manage various stages of campaign planning, from data analysis to developing audience strategies across different channels, including linear TV through a VideoAmp integration. The platform also facilitates the execution of media plans. Beta testing of Cora reportedly reduced marketing planning cycles by 50%, with over 95% of clients experiencing significantly faster workflows, according to DeepIntent founder and CEO Chris Paquette.
Why It's Important?
The introduction of DeepIntent's Cora platform is significant for the U.S. pharmaceutical marketing industry, which is facing increasing complexity due to the development of specialized drugs targeting smaller patient populations. As more than 100 medications are in stage 1 and 2 of FDA clinical trials, many designed for conditions affecting fewer than 10,000 people globally, efficient and precise ad targeting becomes crucial. Cora aims to make the commercialization of these small-population drugs financially viable by radically rethinking how they are brought to market. This shift towards agentic AI platforms could set a new standard for efficiency and precision in healthcare advertising, potentially benefiting pharmaceutical companies by optimizing their marketing spend and reaching highly specific patient demographics more effectively. The platform's ability to integrate new data, including payer and drug coverage signals through its Helix application, further enhances its value by providing a comprehensive view of the healthcare market while protecting patient privacy.
What's Next?
DeepIntent plans to continue enhancing Cora by powering it with new data, including signals related to payers and drug coverage, accessible through its Helix application. This ongoing data integration will further refine the platform's ability to provide targeted and privacy-compliant healthcare advertising solutions. The success of Cora could encourage other adtech companies in the healthcare sector to accelerate their adoption and development of AI-powered tools, potentially leading to a broader industry shift towards agentic marketing platforms. As more specialized drugs gain FDA approval in the coming decade, the demand for efficient and precise marketing solutions like Cora is expected to grow, influencing how pharmaceutical brands approach their advertising strategies and media investments. The platform's impact on reducing planning times and improving workflow efficiency could become a benchmark for future innovations in the sector.
Beyond the Headlines
The launch of Cora highlights a broader trend in the advertising technology (adtech) industry: the increasing reliance on AI and data as core assets. While Cora promises enhanced efficiency and precision in pharmaceutical marketing, it also underscores the ethical and privacy considerations inherent in handling sensitive healthcare data. DeepIntent's emphasis on protecting patient privacy through its Helix application, which aggregates healthcare data, is crucial in an industry heavily regulated by HIPAA and other privacy laws. The platform's ability to navigate these complexities while delivering targeted campaigns could influence regulatory discussions around AI in advertising, particularly in sensitive sectors like healthcare. Furthermore, the move towards 'agentic' AI, where AI systems can execute tasks with conversational language, represents a significant leap in automation, potentially reshaping the roles of human marketers and demanding new skill sets focused on AI oversight and strategy rather than manual execution.
